Summer Sale

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Get 30% Off

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Daniel Ajona

Assistant Professor

Universidad de Navarra

Spain

Has grant

This profile is automatically generated from trusted academic sources.

Google Scholar

ORCID

How do I reach out?

Meet Kite AI

Contact this professor

ORCID

Google Scholar

Research Interests

Immunology

100%

Cell Biology

30%

Cancer Biology

80%

Inflammatory Biology

40%

Tumor Suppressor

40%

Macrophage Biology

30%

Immunotherapy

20%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Recent Grants

Grant: Close

Ayuno temporal como método para mejorar la actividad antitumoral y disminuir los efectos secundarios de la inmunoterapia frente al cáncer de pulmón

Open Date: 2021-12-01

Close Date: 2023-12-01

Grant: Close

La restricción calórica como herramienta para potenciar la eficacia y minimizar la toxicidad de la inmunoterapia frente al cáncer de pulmón

Open Date: 2021-12-01

Close Date: 2024-12-01

Grant: Close

Identificación de marcadores asociados a respuesta a inhibidores de PARP e inmunoterapia en cáncer de ovario recurrente

Open Date: 2021-01-01

Close Date: 2022-12-01

Grant: Close

Modulación del sistema del complemento para mejorar la actividad antitumoral y disminuir los efectos secundarios de la inmunoterapia frente al cáncer de pulmón

Open Date: 2021-01-01

Close Date: 2023-12-01

Grant: Close

Combinatorial Immunotherapies in sarcomas in a novel GEMM platform: Identification of Therapeutic Efficacy and Anticipating Adverse Events.

Open Date: 2020-10-01

Close Date: 2023-10-01

Daniel Ajona

Assistant Professor

How do I reach out?

Contact this professor

Research Interests

Ask ApplyKite AI

Recent Grants

Articles21

Co-targeting of epigenetic regulators and BCL-XL improves efficacy of immune checkpoint blockade therapy in multiple solid tumors.

Dual ENPP1/ATM depletion blunts DNA damage repair boosting radioimmune efficacy to abrogate triple-negative breast cancer.

The C5a/C5aR1 Axis Promotes Migration of Tolerogenic Dendritic Cells to Lymph Nodes, Impairing the Anticancer Immune Response.

Insights and perspectives into the discovery of complement-related biomarkers in cancer

The complement system in clinical oncology: Applications, limitations and challenges.

Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation.

Fasting and fasting-mimicking conditions in the cancer immunotherapy era.

A novel [89Zr]-anti-PD-1-PET-CT to assess response to PD-1/PD-L1 blockade in lung cancer

Plasma fractalkine contributes to systemic myeloid diversity and <scp>PD‐L1</scp>/<scp>PD</scp>‐1 blockade in lung cancer

Tumor ENPP1(CD203a)/Haptoglobin Axis Exploits Myeloid-Derived Suppressor Cells to Promote Post-Radiotherapy Local Recurrence in Breast Cancer.

Gemcitabine-mediated depletion of immunosuppressive dendritic cells enhances the efficacy of therapeutic vaccination

The complement system as a regulator of tumor-promoting activities mediated by myeloid-derived suppressor cells

Complement C5a induces the formation of neutrophil extracellular traps by myeloid-derived suppressor cells to promote metastasis.

Two alternative cell line models for the study of multiorganic metastasis and immunotherapy in Lung Squamous Cell Carcinoma.

Persistence of High Levels of Serum Complement C5a in Severe COVID-19 Cases After Hospital Discharge.

The Complement System in Ovarian Cancer: An Underexplored Old Path

A model based on the quantification of complement C4c, CYFRA 21-1 and CRP exhibits high specificity for the early diagnosis of lung cancer

Molecular biomarkers in early stage lung cancer

SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation

Characterization of the perioperative changes of exosomal immune-related cytokines induced by prostatectomy in early-stage prostate cancer patients.

Id1 and PD-1 Combined Blockade Impairs Tumor Growth and Survival of <i>KRAS</i>-mutant Lung Cancer by Stimulating PD-L1 Expression and Tumor Infiltrating CD8<sup>+</sup> T Cells.

Collaborators11

Marta Santisteban

Ruben Pio

Diego Serrano

marisol gonzalez-huarriz

Jose Maria Lopez-Picazo

Juan José Lasarte

Graziella Bosco

Cristina Bértolo

Enrique Conde-Gallastegi

Jose Yuste

Nerea Varo

How do I reach out?